Evidence against the presence of an anandamide transporter
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
On the basis of temperature dependency, saturability, selective inhibition, and substrate specificity, it has been proposed that an anandamide transporter exists. However, all of these studies have examined anandamide accumulation at long time points when downstream effects such as metabolism and intracellular sequestration are operative. In the current study, we have investigated the initial rates (<1 min) of anandamide accumulation in neuroblastoma and astrocytoma cells in culture and have determined that uptake is not saturable with increasing concentrations of anandamide. However, anandamide hydrolysis, after uptake in neuroblastoma cells, was saturable at steady-state time points (5 min), suggesting that fatty acid amide hydrolase (FAAH) may be responsible for observed saturation of uptake at long time points. In general, arvanil, olvanil, and N -(4-hydroxyphenyl)arachidonylamide (AM404) have been characterized as transport inhibitors in studies using long incubations. However, we found these “transport inhibitors” did not inhibit anandamide uptake in neuroblastoma and astrocytoma cells at short time points (40 sec or less). Furthermore, we confirmed that these inhibitors in vitro were actually inhibitors of FAAH. Therefore, the likely mechanism by which the transport inhibitors raise anandamide levels to exert pharmacological effects is by inhibiting FAAH, and they should be reevaluated in this context. Immunofluorescence has indicated that FAAH staining resides mainly on intracellular membranes of neuroblastoma cells, and this finding is consistent with our observed kinetics of anandamide hydrolysis. In summary, these data suggest that anandamide uptake is a process of simple diffusion. This process is driven by metabolism and other downstream events, rather than by a specific membrane-associated anandamide carrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Deutsch, D. G., & Chin, S. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90486-g · Cited by 702
Self-citationCannabinoids control spasticity and tremor in a multiple sclerosis model
Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., & Layward, L. (2000) · Nature · doi:10.1038/35003583 · Cited by 532
Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling
Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C., & Cravatt, B. F. (2002) · Science · doi:10.1126/science.1076535 · Cited by 490
Molecular characterization of human and mouse fatty acid amide hydrolases
Giang, D. K., & Cravatt, B. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2238 · Cited by 429
Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes
Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., & Di Marzo, V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3315 · Cited by 369
De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agrò, A., & Di Marzo, V. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008555200 · Cited by 355
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Endocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
“It must be emphasized, however, that there is no molecular evidence for the existence of the EMT, and that some authors have suggested that this process might uniquely depend on endocannabinoid intracellular hydrolysi”
Anandamide and vanilloid TRPV1 receptors
Ross, R. A. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705467 · Cited by 604
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Ahn, K., McKinney, M. K., & Cravatt, B. F. (2008) · Chemical Reviews · doi:10.1021/cr0782067 · Cited by 529
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
The endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Biochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Di Marzo, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 383
Di Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
SUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Cannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Identification of intracellular carriers for the endocannabinoid anandamide
Kaczocha, M., Glaser, S. T., & Deutsch, D. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901515106 · Cited by 326
Self-citationCannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 255
An introduction to the endocannabinoid system: from the early to the latest concepts
De Petrocellis, L., & Di Marzo, V. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.013 · Cited by 251
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., & Piomelli, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400997101 · Cited by 230
Ronesi, J., Gerdeman, G. L., & Lovinger, D. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5214-03.2004 · Cited by 228
“These compounds would be expected to inhibit FAAH activity in the postsynaptic neuron, leading to decreased AEA uptake (Glaser et al., 2003) that would, if anything, enhance LTD and the eCB actions.”
BackgroundEndocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia
Mallet, C., Daulhac, L., Bonnefont, J., Ledent, C., Etienne, M., Chapuy, E., Libert, F., & Eschalier, A. (2008) · Pain · doi:10.1016/j.pain.2008.03.030 · Cited by 223
“Anandamide and 2-arachidonoylglycerol, two endogenous ligands of CB1 and CB2 receptors, mainly metabolized by the fatty acid amide hydrolase (FAAH), and the monoacylglycerol lipase, respectively, induce antinociceptive effects [24,51].”
BackgroundInfluentialMitrirattanakul, S., Ramakul, N., Guerrero, A. V., Matsuka, Y., Ono, T., Iwase, H., Mackie, K., Faull, K. F., & Spigelman, I. (2006) · Pain · doi:10.1016/j.pain.2006.06.016 · Cited by 207
“Then, AEA either diffuses (Glaser et al., 2003) or is actively transported into cells (Patricelli and Cravatt, 2001) and is rapidly degraded by the membrane-bound fatty acid amide hydrolase (FAAH) to arachidonic acid.”
BackgroundThe endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203
“In particular, studies supporting a specific transporter have been criticized because anandamide accumulation is assessed over prolonged periods of time when metabolism and intracellular sequestration become relevant factors (Glaser et al., 2003).”
BackgroundGoods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
A catalytically silent FAAH-1 variant drives anandamide transport in neurons
Fu, J., Bottegoni, G., Sasso, O., Bertorelli, R., Rocchia, W., Masetti, M., Guijarro, A., Lodola, A., Armirotti, A., Garau, G., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.2986 · Cited by 175
“Nevertheless, the molecular entity (or entities) involved in anandamide translocation is still unknown, and the mechanistic bases of this process remain controversia”
BackgroundTransport of endocannabinoids across the plasma membrane and within the cell
Fowler, C. J. (2013) · The FEBS Journal · doi:10.1111/febs.12212 · Cited by 168
The Endocannabinoid System in Human Keratinocytes
Maccarrone, M., Di Rienzo, M., Battista, N., Gasperi, V., Guerrieri, P., Rossi, A., & Finazzi-Agrò, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303994200 · Cited by 166
Mechanisms of ADRF release from rat aortic adventitial adipose tissue
Dubrovska, G., Verlohren, S., Luft, F. C., & Gollasch, M. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00656.2003 · Cited by 165
“AM-404 (10 M), an inhibitor of carrier-mediated anandamide transport into nerves inhibiting anandamide inactivation in vivo (6), did not affect vasocontraction of ( )fat and ( )fat rings (n 4 each; data not shown).”
BackgroundSaario, S. M., Savinainen, J. R., Laitinen, J. T., Järvinen, T., & Niemi, R. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.12.003 · Cited by 163
Zhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.009 · Cited by 99
Fatty Acid Amide Hydrolase: A Gate-Keeper of the Endocannabinoid System
Fezza, F., De Simone, C., Amadio, D., & Maccarrone, M. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_4 · Cited by 99
La Rana, G., Russo, R., Campolongo, P., Bortolato, M., Mangieri, R. A., Cuomo, V., Iacono, A., Raso, G. M., Meli, R., Piomelli, D., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100792 · Cited by 97
Endocannabinoids and pregnancy.
Taylor, A. H., Amoako, A. A., Bambang, K., Karasu, T., Gebeh, A., Lam, P. M. W., Marzcylo, T. H., & Konje, J. C. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.03.012 · Cited by 89
Barrière, D. A., Mallet, C., Blomgren, A., Simonsen, C., Daulhac, L., Libert, F., Chapuy, E., Etienne, M., Högestätt, E. D., Zygmunt, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070690 · Cited by 62
“The selectivity towards TRPV1 is even larger for arvanil and olvanil, which both are weak inhibitors of anandamide uptake and degradation [10,23,25–27].”
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models
Mitchell, V. A., Greenwood, R., Jayamanne, A., & Vaughan, C. W. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04692.x · Cited by 43
Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats
RAWLS, S., DING, Z., & COWAN, A. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.03.011 · Cited by 35
Rodella, L. F., Borsani, E., Rezzani, R., Ricci, F., Buffoli, B., & Bianchi, R. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.031 · Cited by 32
Paracetamol: Update on its Analgesic Mechanism of Action
Mallet, C., Eschalier, A., & Daulhac, L. (2017) · Pain Relief - From Analgesics to Alternative Therapies · doi:10.5772/66649 · Cited by 11
“CB1 receptor AM404 is able to indirectly activate the cannabinoid receptor CB1 by inhibiting the degradation [25] and reuptake [26, 27] of anandamide.”
Background
Metadata
- Authors
- Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M., & Deutsch, D. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-03-24
- Volume
- 100
- Issue
- 7
- Pages
- 4269-4274
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2084652074
- Cited by
- 279
- References
- 51
- FWCI
- 22.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.